Philadelphia, 8 December, 2023 – Global law firm Hogan Lovells advised EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) on its US$230 million follow-on public offering of 13,529,411 shares of common stock at a public offering price of US$17.00 per share. J.P. Morgan, TD Cowen and Guggenheim Securities acted as joint book running managers for the offering. Cantor also acted as a book running manager for the offering. Mizuho and Laidlaw & Company (UK) Ltd. acted as co-managers for the offering.
EyePoint Pharmaceuticals is a clinical-stage company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
The Hogan Lovells team was led by capital markets partners Steve Abrams and Stephen Nicolai (both based in Philadelphia) senior associate David Will (New York), and associate Kayvon Paul (Philadelphia).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
